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Abstract
Objective: The role of mitochondrial function in the complex pathogenesis of type 2 diabetes is not yet completely
understood. Therefore, the aim of this study was to investigate serum concentrations of short-, medium- and long-chain
acylcarnitines as markers of mitochondrial function in volunteers with normal, impaired or diabetic glucose control.
Methods: Based on a 75 g oral glucose tolerance test, 1019 studied subjects were divided into a group with normal glucose
tolerance (NGT; n = 636), isolated impaired fasting glycaemia (IFG; n = 184), impaired glucose tolerance (IGT; n = 87) or type 2
diabetes (T2D; n = 112). Serum concentrations of free carnitine and 24 acylcarnitines were measured by mass spectrometry.
Results: Serum levels of acetylcarnitine (C2), propionylcarnitine (C3), octanoylcarnitine (C8), malonylcarnitine/hydro-
xybutyrylcarnitine (C3DC+C4OH), hexanoylcarnitine (C6), octenoylcarnitine (C8:1), decanoylcarnitine (C10), decenoylcarni-
tine (C10:1), dodecanoylcarnitine (C12), tetradecenoylcarnitine (C14:1), tetradecadienylcarnitine (C14:2), hydroxytetradeca-
noylcarnitine (C14OH), hydroxyhexadecanoylcarnitine (C16OH) and octadecenoylcarnitine (C18:1) were significantly
different among the groups (all p,0.05 adjusted for age, gender and BMI). Between the prediabetic states C14:1, C14:2
and C18:1 showed significantly higher serum concentrations in persons with IGT (p,0.05). Compared to T2D the IFG and
the IGT subjects showed lower serum concentrations of malonylcarnitine/hydroxybutyrylcarnitine (C3DC+C4OH) (p,0.05).
Conclusion: Alterations in serum concentrations of several acylcarnitines, in particular tetradecenoylcarnitine (C14:1),
tetradecadienylcarnitine (C14:2), octadecenoylcarnitine (C18:1) and malonylcarnitine/hydroxybutyrylcarnitine (C3DC+C4OH)
are associated not only with T2D but also with prediabetic states.
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Introduction
Obesity and insulin resistance are considered to be crucial
predictors in the development of type 2 diabetes (T2D) [1].
Moreover, insulin resistance is tightly linked with alterations in
lipid metabolism which may consequently lead to increased risk
for coronary heart disease [2,3].
The mitochondrial function seems to play a significant role in
the complex pathogenesis of insulin resistance [4–6]. Acylcarni-
tines belong to the group of markers for mitochondrial function,
specifically for beta oxidation of fatty acids. They are synthesized
by the enzyme carnitine palmitoyltransferase 1 (CPT 1) that is
responsible for the transport of fatty acids into the mitochondrial
matrix [7,8]. Incomplete fatty acid oxidation results in elevated
acylcarnitine concentrations [9], which is used in newborn
screening to detect metabolic disorders [10]. It has also been
described that certain acylcarnitines are lower in obese women
with polycystic ovary syndrome in comparison to controls with
similar BMI [11].
Recent studies suggest that concentrations of various acylcarni-
tines are also associated with insulin resistance and T2D [12–15].
However, little is known about the relationship between alterations
in serum levels and prediabetic states such as isolated impaired
fasting glycaemia (IFG) or impaired glucose tolerance (IGT).
Therefore, the aim of this study was to elucidate alterations in
serum levels of short-, medium- and long-chain acylcarnitines with
respect to the prediabetic states such as IFG or IGT in addition to
normal glucose tolerance (NGT) and T2D.
Materials and Methods
Study population
All subjects are part of a sample from a population from Eastern
Germany, the Sorbs [16,17]. Based on a 75 g oral glucose
tolerance test (oGTT) and according to the criteria of the
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American Diabetes Association [18] 1019 individuals were divided
into groups of normal glucose tolerance (NGT, n = 636), isolated
impared fasting glycaemia (IFG, n = 184), impaired glucose
tolerance (IGT, n = 87) and type 2 diabetes (T2D, n = 112).
Individuals with isolated IFG were defined by a fasting plasma
glucose $5.6 mmol/l and #6.9 mmol/l. Patients with IGT were
defined by a fasting plasma glucose ,7.0 mmol/l and a 120-min
plasma glucose $7.8 mmol/l and ,11.1 mmol/l. T2D was
defined by 120-min plasma glucose $11.1 mmol/l or fasting
plasma glucose $7.0 mmol/l and individuals with NGT were
defined by a fasting plasma glucose ,5.6 mmol/l and a 120-min
plasma glucose ,7.8 mmol/l.
The study was approved by the ethics committee of the
University Hospital of Leipzig and all subjects provided written
informed consent before taking part in the study.
Measurement of body fat content and glucose
metabolism
Body fat percentage was measured by body impedance analysis
(BIA). BIA was performed with BIA-2000-S (Data Input GmbH,
Darmstadt, Germany) and evaluated with the software Nutri3
(Data Input GmbH). The oGTT was performed after an overnight
fast with 75 g standardized glucose solution. All baseline blood
samples were collected between 8:00 and 10:00 am.
Mass spectrometric measurement of acylcarnitines
The metabolite quantitation of the serum samples was
performed subsequently during 2011 with a routine method used
for confirmation and follow-up diagnostics of inborn errors of
metabolism in batches of clinical and randomly admixed study
sample series. The targeted metabolite profiling was focused on
the determination of free and 24 acyl carnitines and based on the
methods of Vernez et al. [19]. For our accredited (ISO/IEC
17025, STS- 259) in-house method 30 mL of serum were diluted
in 270 mL aqua puriss. and 30 mL of this solution were mixed with
100 mL methanolic standard solution NSK-B (Cambridge Iso-
topes, Andover, MA, USA; preparation according to the attached
CIL instruction). Of this final solution, 4 mL were injected in our
analytical system consisting of an API 4000 Q-Trap LC-MS/MS
system (ABSciex, Zug, Switzerland) and an Agilent 1100 HPLC
system (Agilent, Basel, Switzerland) consisting of a vacuum
microdegaser, a quaternary pump, a thermostated autosampler
and a column compartment module with a Macherey - Nagel
column Nucleodur C8 Gravity (12562 mm, 5 mm).
The separation was performed at a flow rate of 0.2 mL/min at
30uC. Solvent A was an aqueous solution of 250 mL water (Milli-
Q-Reference; Millipore AG, Zug, Switzerland), 325 mL hepta-
fluorobutyric acid (Fluka, Switzerland, for ion chromatography)
and 170 mg ammonium acetate (Fluka, Switzerland, eluent
additive for LC-MS). Solvent B was a methanolic solution of
250 mL methanol (Riedel-de Haen, Switzerland, LC-MS Chro-
masolv), 325 mL heptafluorobutyric acid and 170 mg ammonium
acetate. A linear gradient program was used: 0 min, 95% A and
5% B, 2 min, 95%A and 5%B, 6 min, 10%A and 90%B, 14 min,
10%A and 90%B, 14.1 min, 5%A and 95%B, 16 min, 5%A and
95%B, 17 min, 95%A and 5%B, reequilibration 17–25 min.
Measurements and quantitation of the carnitines were per-
formed by using two specific transitions (ESI positive ionization
with multiple reaction monitoring) for each carnitine at unit
resolution (Software Analyst 1.5, ABSciex, Zug, Switzerland) as
well as in-house MS ExcelTM macros. The acyl carnitine
concentrations are reported in mmol/L. Carnitine, C2-, C3-,
C4-, C5-, C8-, C14-, and C16-carnitine were quantified directly
via the internal standard, the other carnitines in accordance to the
isotope-labeled standards for C5-, C8-, C14-, and C16-carnitine
with empirical correction factors derived from certified control
materials (Chromsystems, MassCheck Amino Acids and Acylcar-
nitines Dried Blood Spot Controls, Germany and Recipe,
ClinChek Whole Blood Control, Germany). A quality control
plasma sample was prepared and analyzed with every batch of the
study samples to verify the stability of the calculated concentra-
tions during the measurements. For determination of the inter-day
precision, provided as the percentages of the coefficient of
variation (CV), 10 replicates of a quality control were analyzed
on 10 different days. For concentrations $0.2 mmol/l the CV was
,10% and for concentrations ,0.2 mmol/L the CV was ,35%.
Statistical analyses
Data are shown as means 6 standard deviation. Before
statistical analysis, non-normally distributed parameters were
logarithmically transformed to approximate a normal distribution.
A general linear model analysis including age, gender and BMI
as covariates was performed for each acylcarnitine. Non-
standardized residuals were then taken forward as a new
dependent variable in the ANOVA analysis comparing all four
phenotypic groups (NGT, IFG, IGT and T2D). For p-values
,0.05 in the ANOVA a Tukey-HSD posthoc test was performed.
To assess the relationship between acylcarnitines and body fat
or waist to hip ratio a linear regression model was performed
adjusted for age and gender.
Statistical analysis was performed using IBM SPSS Statistics
version 20.0.
Results
Free carnitine, acetylcarnitine (C2), propionylcarnitine (C3),
butyrylcarnitine (C4), isovalerylcarnitine (C5), hexanoylcarnitine
(C6) and hexadecenoylcarnitine (C16:1) were significantly associ-
ated with increased body fat and waist to hip ratio (Table 1). In
contrast octadecanoylcarnitine (C18) was associated with de-
creased body fat (p = 8.2761025, beta =20.124) and WHR
(p = 0.001, beta =20.141). Serum concentration of octenoylcar-
nitine (C8:1) was associated with increased body fat
(p = 4.7861025, beta = 0.131), while tetradecadienylcarnitine
(C14:2) showed association with decreased body fat (p = 0.038,
beta =20.069). Hexadecanoylcarnitine (C16), hydroxytetradeca-
noylcarnitine (C14OH) and hydroxyhexadecanoylcarnitine
(C16OH) showed positive correlations with WHR but not with
body fat (Table 1).
However, there were no associations between body fat or WHR
with other acylcarnitines (Table 1).
A group of 410 men and 609 women with an age range from 18
to 88 years and BMI from 15.4 to 50.3 kg/m2 were divided into
groups of NGT, IFG, IGT and T2D (Table 2). Age, BMI and the
other parameters (% body fat, waist and hip circumference, WHR)
were significantly different in comparison of all groups (p,0.001).
In comparison of the four groups there were significant (age,
gender and BMI adjusted) differences in the serum levels of
acetylcarnitine (C2), propionylcarnitine (C3), octanoylcarnitine
(C8), malonylcarnitine/hydroxybutyrylcarnitine (C3DC+C4OH),
hexanoylcarnitine (C6), octenoylcarnitine (C8:1), decanoylcarni-
tine (C10), decenoylcarnitine (C10:1), dodecanoylcarnitine (C12),
tetradecenoylcarnitine (C14:1), tetradecadienylcarnitine (C14:2),
hydroxytetradecanoylcarnitine (C14OH), hydroxyhexadecanoyl-
carnitine (C16OH) and octadecenoylcarnitine (C18:1) (Table 3).
Persons with IGT had higher concentrations of C2, C14:1 and
C18:1 compared to individuals with NGT, while none of the
acylcarnitines showed a significant difference of serum levels in
Acylcarnitines in Prediabetes
PLOS ONE | www.plosone.org 2 December 2013 | Volume 8 | Issue 12 | e82459
comparison of NGT and IFG. Patients with T2D showed a
significantly increased concentration of C2, C3DC+C4OH, C6,
C8:1, C10:1, C14:1, and C16OH in comparison of individuals
with NGT. Only C14:1 (p = 0.001), C14:2 (p = 0.004) and C18:1
(p = 0.019) showed a significant altered serum level between IFG
and IGT. Compared to patients with T2D, concentrations of
C3DC+C4OH were significantly lower in individuals with IFG
(p = 1.9761026) or IGT (p = 0.032) (Figure 1).
However, there were no significant differences in serum levels of
free carnitine, butyrylcarnitine (C4), isovalerylcarnitine (C5),
tetradecanoylcarnitine (C14), hexadecanoylcarnitine (C16), succi-
nylcarnitine (C4DC), tiglylcarnitine (C5:1), hydroxyvalerylcarni-
tine (C5OH), glutarylcarnitine (C5DC), hexadecenoylcarnitine
(C16:1) and octadecanoylcarnitine (C18) between the groups
(Table 3).
Discussion
The clinical relevance of differentiating the prediabetic states of
isolated impaired fasting glycaemia and impaired glucose toler-
ance has previously been shown by others [20,21]. It has been
suggested that different pathomechanisms lead to either an
isolated IFG or an isolated IGT [21]. However, little is known
about the role of acylcarnitines in differentiating these prediabetic
states from each other as well as from normal glucose tolerance or
T2D. We addressed this issue in the present study. Our analyses
reveal significant differences in concentrations of C2, C3, C8,
C3DC+C4OH, C6, C8:1, C10, C10:1, C12, C14:1, C14:2,
C14OH, C16OH and C18:1 between the prediabetic conditions.
The most profound relationship with the metabolic phenotypes
was observed for the serum concentration of malonylcarnitine/
hydroxybutyrylcarnitine (C3DC+C4OH). C3DC+C4OH was also
the only metabolite which was significantly higher in patients with
T2D in comparison to individuals with IGT. On the other hand,
tetradecenoylcarnitine (C14:1), tetradecadienylcarnitine (C14:2)
and octadecenoylcarnitine (C18:1) were the only acylcarnitines
that showed a significant difference between the two prediabetic
states in our study. Others have reported that C14:1 decreased
after glucose ingestion [22] and increased after a fasting period
[23]. This might be due to the higher fasting free fatty acid plasma
Table 1. Association between acylcarnitines and body fat or
waist to hip ratio.
Acylcarnitines Body fat [%] Waist to hip ratio
Beta p-value Beta p-value
free carnitine 0.191 3.73610210 0.233 3.3361028
C2 0.076 0.016 0.114 0.009
C3 0.196 2.89610211 0.265 7.54610211
C4 0.08 0.016 0.141 0.002
C5 0.161 1.3661027 0.239 1.2461028
C8 20.021 0.530 20.05 0.270
C14 20.012 0.715 0.045 0.338
C16 0.047 0.117 0.095 0.023
C3DC +C4OH 0.019 0.602 0.005 0.920
C4DC 20.01 0.819 0.055 0.359
C5:1 20.023 0.512 20.027 0.579
C5OH 0.072 0.093 0.099 0.087
C5DC 20.03 0.379 20.025 0.599
C6 0.136 3.7961025 0.144 0.002
C8:1 0.131 4.7861025 0.077 0.084
C10 20.045 0.180 20.068 0.138
C10:1 20.033 0.314 20.029 0.518
C12 20.064 0.057 20.002 0.961
C14:1 20.039 0.228 20.073 0.103
C14:2 20.069 0.038 20.071 0.117
C14OH 0.03 0.428 0.178 0.0005
C16:1 0.091 0.006 0.137 0.003
C16OH 0.005 0.892 0.121 0.017
C18 20.124 8.2761025 20.141 0.001
C18:1 0.048 0.113 0.038 0.365
Associations were assessed in a linear regression model adjusted for age and
gender. P-values ,0.05 were considered as statistically significant and marked
in bold italic.
doi:10.1371/journal.pone.0082459.t001
Table 2. Characteristics of the study population (N= 1019).
NGT IFG IGT T2D p-value
N (male/female) 636 (215/421) 184 (112/72) 87 (35/52) 112 (48/64)
Age (years) 42.1614.9 53.8613.5 59.2613.1 63.7611.4 ,0.001
[18–80] [19–88] [20–82] [20–87]
BMI (kg/m2) 25.364.2 28.964.5 29.964.7 30.965.5 ,0.001
[15.4–47.4] [19–46.3] [22.2–43] [18.8–50.3]
Body fat (%) 19.268.2 22.968.9 26.269.9 26.9610.5 ,0.001
[5.3–65.4] [8.4–56] [11.1–51.9] [7.5–58.8]
Waist circumference (cm) 85.5611.9 98.2611.8 99.5611.2 102.5613.9 ,0.001
[59–139] [67–133] [72–122] [69–139]
Hip circumference (cm) 101.667.8 106.169 108.3610.3 108.6610.6 ,0.001
[70–141] [90–146] [88–140] [88–146]
Waist to hip ratio 0.8460.09 0.9360.09 0.9260.09 0.9460.09 ,0.001
[0.56–1.3] [0.71–1.13] [0.74–1.15] [0.65–1.18]
Group specific arithmetic means 6 standard deviation and ranges are given for each variable. NGT, normal glucose tolerance; IFG, isolated impaired fasting glycaemia;
IGT, impaired glucose tolerance; T2D, type 2 diabetes
doi:10.1371/journal.pone.0082459.t002
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concentrations in IGT subjects when compared with persons with
IFG [24]. However, it remains to be elucidated why these were the
only carnitines differentially regulated in IGT and IFG.
Higher acetylcarnitine (C2) levels in IGT subjects compared to
NGT have been shown previously [25]. We could confirm this
association in our study.
Several acylcarnitines were significantly increased in patients
with T2D in comparison with individuals with NGT. One could
argue that T2D is typically associated with higher body fat
percentage and higher load of free fatty acids [26], but some of
the acylcarnitines, such as C3DC+C4OH, C10:1 or C14:1,
were not associated with body fat in our study. It was specu-
lated that acylcarnitines are involved in the linkage between
amino-acid-metabolism and type 2 diabetes [27]. Fiehn et al.
showed that concentrations of leucine and valine were increased in
type 2 diabetic obese women and also correlated with concentra-
tions of plasma acylcarnitines [27]. So maybe a diabetes specific
dysregulation of fatty acid oxidation and mitochondrial function
leads to the higher amount of these acylcarnitines.
In the present study we confirmed previously reported
associations between acylcarnitines serum concentrations and
body fat [28]. We showed, that percentage of body fat correlated
positively with serum levels of free carnitine and the acylcarnitines
C2, C3, C4, C5, C6, C8:1 and C16:1, but negatively with
acylcarnitines C14:2 and C18. It is likely that the higher body fat
correlates with an upregulated or maybe overloaded beta
oxidation of fatty acids, which leads predominantly to higher
amounts of short- or medium-chain-acylcarnitines.
It has been shown previously that long-chain-acylcarnitines
decreased after a long aerobic exercise program in obese women
[29]. In contrast, medium-chain acylcarnitines were reported to be
increased after moderate intensity exercise [30]. Furthermore, an
association between impaired muscle function and acylcarnitines
has been described [31].
It could be shown that medium-chain acylcarnitines increase in
persons with high fasting respiratory quotient as a risk factor for
metabolic syndrome [32]. So these acylcarnitines are markers for
incomplete fatty acid oxidation. In our study medium-chain and
long-chain acylcarnitines were associated with the two prediabetic
states, suggesting a linkage between the differences in prediabetic
states and an incomplete or overloaded fatty acid oxidation.
Supported by our findings that certain acylcarnitines did not
show any association with body fat or WHR, fat mass and fat
distribution do not seem to be the only factors possibly explaining
higher serum levels of these metabolites.
In conclusion, our study showed that alterations in serum
concentrations of several acylcarnitines, in particular decenoyl-
carnitine (C14:1), tetradecadienylcarnitine (C14:2), octadecenoyl-
carnitine (C18:1) and malonylcarnitine/hydroxybutyrylcarnitine
(C3DC+C4OH) are associated not only with T2D but also with
prediabetic states. The data further support the existence of
various pathomechanisms being responsible for prediabetic states
of IFG or IGT. Finally, our findings suggest that higher
concentrations of acylcarnitines associated with T2D cannot be
explained by exclusively obesity.
Acknowledgments
We thank Sandra Eggimann and Peter Rhyn for their analytic support.
We thank all those who participated in the studies. We would like to
acknowledge excellent technical assistance by Beate Enigk. We would like
to thank Joachim Thiery (Institute of Laboratory Medicine, Clinical
Chemistry and Molecular Diagnostics, University of Leipzig) for clinical
chemistry services.
Author Contributions
Conceived and designed the experiments: AT GMF ABL. Performed the
experiments: GMF ABL. Analyzed the data: MM. Contributed reagents/
materials/analysis tools: GMF ABL. Wrote the paper: MM AT PK MS
GMF ABL. Sample collection: AT PK MS.
References
1. Stumvoll M, Goldstein BJ, van Haeften TW (2005) Type 2 diabetes: principles of
pathogenesis and therapy. Lancet 365 (9467): 1333–1346.
2. Savage DB, Petersen KF, Shulman GI (2007) Disordered lipid metabolism and
the pathogenesis of insulin resistance. Physiol. Rev. 87 (2): 507–520.
3. Abbasi F, Brown BW, Lamendola C, McLaughlin T, Reaven GM (2002)
Relationship between obesity, insulin resistance, and coronary heart disease risk.
J. Am. Coll. Cardiol. 40 (5): 937–943.
4. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, et al. (2008)
Mitochondrial overload and incomplete fatty acid oxidation contribute to
skeletal muscle insulin resistance. Cell Metab. 7 (1): 45–56.
Figure 1. Serum concentration for C14:1-carnitine (A) and
C3DC+C4OH-carnitine (B) in the different groups. Shown are
means + SEM for NGT (normal glucose tolerance), IFG (impaired fasting
glycaemia), IGT (impaired glucose tolerance) and T2D (type 2 diabetes);
* p,0.05 vs. T2D, # p,0.01 vs. IGT
doi:10.1371/journal.pone.0082459.g001
Acylcarnitines in Prediabetes
PLOS ONE | www.plosone.org 6 December 2013 | Volume 8 | Issue 12 | e82459
5. Kelley DE, He J, Menshikova EV, Ritov VB (2002) Dysfunction of
mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51 (10):
2944–2950.
6. Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, et al. (2010)
Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and
identification of a marker of glucolipotoxicity. Obesity (Silver Spring) 18 (9):
1695–1700.
7. McGarry JD, Brown NF (1997) The mitochondrial carnitine palmitoyltransfer-
ase system. From concept to molecular analysis. Eur. J. Biochem. 244 (1): 1–14.
8. Indiveri C, Iacobazzi V, Tonazzi A, Giangregorio N, Infantino V, et al. (2011)
The mitochondrial carnitine/acylcarnitine carrier: function, structure and
physiopathology. Mol. Aspects Med. 32(4-6): 223–233.
9. Koves TR, Li P, An J, Akimoto T, Slentz D, et al. (2005) Peroxisome
proliferator-activated receptor-gamma co-activator 1alpha-mediated metabolic
remodeling of skeletal myocytes mimics exercise training and reverses lipid-
induced mitochondrial inefficiency. J. Biol. Chem. 280 (39): 33588–33598.
10. van Hove JL, Zhang W, Kahler SG, Roe CR, Chen YT, et al. (1993) Medium-
chain acyl-CoA dehydrogenase (MCAD) deficiency: diagnosis by acylcarnitine
analysis in blood. Am. J. Hum. Genet. 52 (5): 958–966.
11. Vigerust NF, Bohov P, Bjørndal B, Seifert R, Nyga˚rd O, et al. (2012) Free
carnitine and acylcarnitines in obese patients with polycystic ovary syndrome
and effects of pioglitazone treatment. Fertil. Steril. 98 (6): 1620–1626.e1.
12. Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, et al. (2009) Plasma
acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and
altered tricarboxylic acid cycle activity in type 2 diabetic African-American
women. J. Nutr. 139 (6): 1073–1081.
13. Ha CY, Kim JY, Paik JK, Kim OY, Paik Y, et al. (2012) The association of
specific metabolites of lipid metabolism with markers of oxidative stress,
inflammation and arterial stiffness in men with newly diagnosed type 2 diabetes.
Clin. Endocrinol.(Oxf) 76 (5): 674–682.
14. Tai ES, Tan MLS, Stevens RD, Low YL, Muehlbauer MJ, et al. (2010) Insulin
resistance is associated with a metabolic profile of altered protein metabolism in
Chinese and Asian-Indian men. Diabetologia 53 (4): 757–767.
15. Huffman KM, Shah SH, Stevens RD, Bain JR, Muehlbauer M, et al. (2009)
Relationships between circulating metabolic intermediates and insulin action in
overweight to obese, inactive men and women. Diabetes Care 32 (9): 1678–
1683.
16. To¨njes A, Koriath M, Schleinitz D, Dietrich K, Bo¨ttcher Y, et al. (2009) Genetic
variation in GPR133 is associated with height: genome wide association study in
the self-contained population of Sorbs. Hum. Mol. Genet 18 (23): 4662–4668.
17. To¨njes A, Zeggini E, Kovacs P, Bo¨ttcher Y, Schleinitz D, et al. (2010)
Association of FTO variants with BMI and fat mass in the self-contained
population of Sorbs in Germany. Eur. J. Hum. Genet 18(1): 104–110.
18. (2013) Diagnosis and classification of diabetes mellitus. Diabetes Care 36 Suppl
1: S67–74.
19. Vernez L, Hopfgartner G, Wenk M, Kra¨henbu¨hl S (2003) Determination of
carnitine and acylcarnitines in urine by high-performance liquid chromatogra-
phy-electrospray ionization ion trap tandem mass spectrometry. J Chromatogr A
984 (2): 203–213.
20. Unwin N, Shaw J, Zimmet P, Alberti KGMM (2002) Impaired glucose tolerance
and impaired fasting glycaemia: the current status on definition and
intervention. Diabet. Med 19 (9): 708–723.
21. Faerch K, Borch-Johnsen K, Holst JJ, Vaag A (2009) Pathophysiology and
aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it
matter for prevention and treatment of type 2 diabetes. Diabetologia 52 (9):
1714–1723.
22. Zhao X, Peter A, Fritsche J, Elcnerova M, Fritsche A, et al. (2009) Changes of
the plasma metabolome during an oral glucose tolerance test: is there more than
glucose to look at. Am. J. Physiol. Endocrinol. Metab. 296(2): E384–93.
23. Costa CC, Almeida IT de, Jakobs C, Poll-The BT, Duran M (1999) Dynamic
changes of plasma acylcarnitine levels induced by fasting and sunflower oil
challenge test in children. Pediatr. Res. 46 (4): 440–444.
24. Abdul-Ghani MA, Molina-Carrion M, Jani R, Jenkinson C, Defronzo RA
(2008) Adipocytes in subjects with impaired fasting glucose and impaired glucose
tolerance are resistant to the anti-lipolytic effect of insulin. Acta Diabetol 45 (3):
147–150.
25. Wang-Sattler R, Yu Z, Herder C, Messias AC, Floegel A, et al. (2012) Novel
biomarkers for pre-diabetes identified by metabolomics. Mol. Syst. Biol 8: 615.
26. Boden G, Shulman GI (2002) Free fatty acids in obesity and type 2 diabetes:
defining their role in the development of insulin resistance and beta-cell
dysfunction. Eur. J. Clin. Invest. 32 Suppl 3: 14–23.
27. Fiehn O, Garvey WT, Newman JW, Lok KH, Hoppel CL, et al. (2010) Plasma
metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2
diabetic obese African-American women. PLoS ONE 5 (12): e15234.
28. Jourdan C, Petersen A, Gieger C, Do¨ring A, Illig T, et al. (2012) Body fat free
mass is associated with the serum metabolite profile in a population-based study.
PLoS ONE 7 (6): e40009.
29. Rodrı´guez-Gutie´rrez R, Lavalle-Gonza´lez FJ, Martı´nez-Garza LE, Landeros-
Olvera E, Lo´pez-Alvarenga JC, et al. (2012) Impact of an exercise program on
acylcarnitines in obesity: a prospective controlled study. J Int Soc Sports Nutr 9
(1): 22.
30. Lehmann R, Zhao X, Weigert C, Simon P, Fehrenbach E, et al. (2010) Medium
chain acylcarnitines dominate the metabolite pattern in humans under moderate
intensity exercise and support lipid oxidation. PLoS ONE 5 (7): e11519.
31. Lum H, Sloane R, Huffman KM, Kraus VB, Thompson DK, et al. (2011)
Plasma acylcarnitines are associated with physical performance in elderly men. J.
Gerontol. A Biol. Sci. Med. Sci. 66 (5): 548–553.
32. Wolf M, Chen S, Zhao X, Scheler M, Irmler M, et al. (2013) Production and
release of acylcarnitines by primary myotubes reflect the differences in fasting fat
oxidation of the donors. J. Clin. Endocrinol. Metab. 98(6): E1137–42.
Acylcarnitines in Prediabetes
PLOS ONE | www.plosone.org 7 December 2013 | Volume 8 | Issue 12 | e82459
